Alladapt Immunotherapeutics’ $100+ Million Financing Round

Goodwin Procter advised Alladapt Immunotherapeutics Inc. on the deal.

Alladapt Immunotherapeutics Inc. announced its $100+ million financing round led by Enavate Sciences, a portfolio company created by Patient Square Capital. Additional investors participating in the financing include Alladapt’s founding investor, Gurnet Point Capital, along with new investors Allerfund, Red Tree Venture Capital, WestRiver Group, and Novartis.

Alladapt is a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy.

Proceeds from this funding round will support the ongoing clinical development of ADP101, Alladapt’s lead product candidate, as well as preparation for a potential pivotal trial, the continued buildout of Alladapt’s manufacturing facility, and investment in further pipeline expansion.

The Goodwin team was led by Deepa Rich (Picture) and Anthony McCusker, with support from Kim Maruncic.

Involved fees earner: Kimberley Maruncic – Goodwin Procter; Anthony McCusker – Goodwin Procter; Deepa Rich – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Alladapt Immunotherapeutics;

Martina Bellini

Author: Martina Bellini